PHAT News and Press, Phathom Pharmaceuticals Inc.

This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026 FLORHAM PARK, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, I...

2026-06-09 17:12:11 ET Phathom Pharmaceuticals, Inc. (PHAT) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 2:40 PM EDT... Read the full article on Seeking Alpha For further details see: Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs ...

2026-06-09 12:37:05 ET I’ve been cautious on Phathom Pharmaceuticals, Inc. ( PHAT ) in the past. This company markets Voquezna in the U.S. for erosive esophagitis, non-erosive GERD, and H. pylori infection. Outside of severe erosive esophagitis, I’ve noted that Voquezn...

31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstracts Independent investigator-initiated studies reported findings on treatment of GERD, H. pylori...

FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the Digestive Disease Week ® (DD...

2026-04-30 17:16:13 ET Image source: The Motley Fool. Thursday, Apr. 30, 2026 at 8 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-04-30 15:32:56 ET More on Phathom Pharmaceuticals Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Phathom Pharmaceuticals, Inc. 20...

2026-04-30 15:31:44 ET Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call April 30, 2026 8:00 AM EDT... Read the full article on Seeking Alpha For further details see: Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript

2026-04-30 07:21:59 ET More on Phathom Pharmaceuticals Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Phathom Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation Phathom Pharmaceuticals, ...

~1.35 million total VOQUEZNA ® prescriptions filled to date $58.3 million in Q1 net revenues, a 104% increase year-over-year Q1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2 million and net cash usage of ~$15 million, reflecting continued expense discipli...